Abstract: A device for monitoring process variations across memory bitcells includes a bitcell inverter that provides an output voltage to be used for identifying skewed corners of the memory bitcells. A first comparator compares the output voltage with a first reference voltage, and a second comparator compares the output voltage with a second reference voltage. The first and the second comparators generate a corner code based on comparison results.

Abstract: A device for monitoring process variations across memory bitcells includes a bitcell inverter that provides an output voltage to be used for identifying skewed corners of the memory bitcells. A first comparator compares the output voltage with a first reference voltage, and a second comparator compares the output voltage with a second reference voltage. The first and the second comparators generate a corner code based on comparison results.

Abstract: Compounds of formula (I) Q-L-W—C(?X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.

Abstract: Compounds of formula (I) Q-L-W—C(?X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.

Abstract: Compounds of formula (I) Q-L-W—C(?X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.

Abstract: Compounds of formula (I) Q-L-W—C(?X)-Z-P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.

Abstract: A method of separating a function of the business logic of an application from a user interface of the application where the business logic and user interface of the application are intermingled is provided. The method includes providing a wrapper interface for the application. The method also includes providing a function of the business logic of the application separated from the user interface of the application through the wrapper interface.

Abstract: The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, Ra, R8, R2, R3 and R4 are as defined in the specification, in the preparation of a medicament for the treatment of C—C chemokine mediated conditions. Novel compounds of formula (I) and pharmaceutical compositions containing them are also described and claimed.

Abstract: The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, X4, Ra, p, R1, Z, Y, R2, R3 and R4 are as defined in the specification, in the preparation of a medicament for the treatment of C—C chemokine mediated conditions, such as inflammatory disease. Certain compounds of formula (I) are novel and these, together with their preparation are also described and claimed.

Abstract: The invention provides a compound of formula (I): [Chemical formula should be inserted here. Please see paper copy.] wherein R1, R2, R3, R3a, R4, R4a, R5, and R6 are as defined; or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and their use as modulators of chemokine activity (especially CCR5 activity).

Abstract: An ink cartridge (1) for a reservoir pen has a body (2) which encloses an ink-chamber (3) that is initially sealed near the front end of the cartridge by a closure formed by a plug (4). The plug (4) sealingly engages in an axial bore (5) which is open to the front end of the cartridge and is slidably mounted in the cartridge body (2) so as to be moved rearwardly by engagement with a peg (34) upon insertion of the cartridge (1) into a pen, thereby allowing ink flow from the ink chamber (3) through the bore (5) and to a writing tip (23) of a nib (22) of the pen. The peg (34) is sized so as to form a seal with the inner surface of the bore (3) when fully inserted thereinto.

Abstract: A method of separating a function of the business logic of an application from a user interface of the application where the business logic and user interface of the application are intermingled is provided. The method includes providing a wrapper interface for the application. The method also includes providing a function of the business logic of the application separated from the user interface of the application through the wrapper interface.

Abstract: A reservoir pen includes a nib, a feed bar defining an ink channel and having an ink port, and a valve for controlling flow of ink from the ink port to an underside of the nib. The valve includes a seat, a valve member, and a resilient element engaging the valve member to bias the valve member away from the ink port toward an open position. The valve member is further positioned to engage the nib to urge the valve member against the resilient element and into sealing contact with the seat. The resilient member is disposed outside of the ink channel in at least the open position.

Abstract: An ink cartridge (1) for a reservoir pen has a body (2) which encloses an ink-chamber (3) that is initially sealed near the front end of the cartridge by a closure formed by a plug (4). The plug (4) sealingly engages in an axial bore (5) which is open to the front end of the cartridge and is slidably mounted in the cartridge body (2) so as to be moved reawardly by engagement with a peg (34) upon insertion of the cartridge (1) into a pen, thereby allowing ink flow from the ink chamber (3) through the bore (5) and to a writing tip (23) of a nib (22) of the pen. The peg (34) is sized so as to form a seal with the inner surface of the bore (5) when fully inserted thereinto.